ArticlePharmacology2008
A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations.
Article in Pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03310749 (A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Gemigliptin and Metformin After Oral Administration in Healthy Mexican Male Subjects), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Gemigliptin and Metformin After Oral Administration in Healthy Mexican Male Subjects
Who cites it
4 citing papers in PubMed.
- Variations in Plasma Levels of Orally Administered Ivermectin Could Hamper Its Potential Drug Repositioning: Results of a Bioequivalence Study in Mexican Population.Pharmaceuticals (Basel, Switzerland) · 2025Article
- P450 Pharmacogenetics in Indigenous North American Populations.Journal of personalized medicine · 2018Review
- Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.Pharmacogenetics and genomics · 2013Article
- Pharmacogenomics of CYP3A: considerations for HIV treatment.Pharmacogenomics · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytochrome P-450 3A4 (CYP3A4) contributes to the metabolism of approximately half the drugs in clinical use today. The aim of the present study was to determine the frequency of the CYP3A4*1B, *2, *4, *5, and *18 alleles amongst both Tepehuan Amerindians, a native group that has inhabited northern Mexico for thousands of years, and Mestizo Mexicans, and to compare the data with those of other populations. Genotyping experiments revealed that 8.8 and 8.0% of the Mestizo and Tepehuano subjects, respectively, carried the CYP3A4*1B allele. Only one Mestizo subject was heterozygous for the CYP3A4*2 variant, while CYP3A4*4, *5 and *18 allelic variants were not detected in either group. On the other hand, the frequencies of the CYP3A4*1B variant in Mestizos and Tepehuanos were similar to those reported for Caucasians, but different from those observed for African and Asian populations.
Indexed as
Identifiers
17952011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.